List of articles in "Drug" category - Page 362

Mexazolam (marketed under the trade names Melex and Sedoxil) is a drug which is a benzodiazepine derivative. Mexazolam has been trialed for anxiety and was found to be effective in […]

Lisdexamfetamine dimesylate (L-lysine-dextroamphetamine dimesylate) is a psychostimulant prodrug of the phenethylamine and amphetamine chemical classes. Its molecular structure consists of dextroamphetamine coupled with the essential amino acid L-lysine.

Tenocyclidine (TCP) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is similar in effects to phencyclidine (PCP) but is considerably more potent. TCP has slightly different binding […]

Eticyclidine (PCE CI-400) is a dissociative anesthetic drug with hallucinogenic effects. It is similar in effects to phencyclidine but is slightly more potent. PCE was developed by Parke-Davis in the […]

Rolicyclidine (PCPy) is a dissociative anesthetic drug with hallucinogenic and sedative effects. It is similar in effects to phencyclidine but is slightly less potent and has less stimulant effects instead […]

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).This drug was developed by EMD Pharmaceuticals.

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a […]

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system. It binds to integrin αIIbβ3 a fibrinogen and fibronectin receptor found on platelets.The drug is designed for the […]

Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer. The antibody itself tacatuzumab is conjugated with tetraxetan a chelator for yttrium-90 […]

Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAPIn 2003 it failed a phase II clinical trial for metastatic colorectal cancer.